sirpα Search Results


94
Miltenyi Biotec anti mouse sirpα pe antibody
Anti Mouse Sirpα Pe Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/CD172a+(SIRP%CE%B1)+Antibody%2C+anti-mouse%2C+REAfinity/pm42323948-73-75-78
Average 94 stars, based on 1 article reviews
anti mouse sirpα pe antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Sino Biological human sirpα v1 mfc
Human Sirpα V1 Mfc, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/Human+SIRP+alpha+%2F+CD172a+Protein/us12577303-449-4-6
Average 94 stars, based on 1 article reviews
human sirpα v1 mfc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc rabbit anti sirpα
Rabbit Anti Sirpα, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRPalpha%2FSHPS1+Rabbit+mAb/pmc06532126-52-35-41
Average 94 stars, based on 1 article reviews
rabbit anti sirpα - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology anti signal regulatory protein α sirpα antibody
Anti Signal Regulatory Protein α Sirpα Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP-%CE%B1+Antibody/pmc05788154-125-15-24
Average 93 stars, based on 1 article reviews
anti signal regulatory protein α sirpα antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc sirpa d6i3m cell signaling technology 47027sf
Sirpa D6i3m Cell Signaling Technology 47027sf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRPalpha%2FSHPS1+Rabbit+mAb/pmc12572286__41416_2025_3137_MOESM1_ESM-8-145-148
Average 93 stars, based on 1 article reviews
sirpa d6i3m cell signaling technology 47027sf - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
R&D Systems recombinant human sirp alpha cd172a fc chimera protein
Recombinant Human Sirp Alpha Cd172a Fc Chimera Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/Recombinant+Human+SIRP+alpha%2FCD172a+Fc+Chimera+Protein%2C+CF/pmc07025889-48-29-36
Average 92 stars, based on 1 article reviews
recombinant human sirp alpha cd172a fc chimera protein - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

85
Santa Cruz Biotechnology anti sirp antibody
FIGURE 6. Binding of elastic lamina degradation peptides (ELDPs) to <t>SIRP</t> . A, co- immunoprecipitation of ELDPs with SIRP and phosphorylation of SIRP . Two tests were conducted. IP, immunoprecipitation. IB, immunoblotting. B, influence of anti-SIRP antibody on the binding <t>of</t> <t>FITC-conjugated</t> ELDPs to SIRP . Curve 1, FITC-conjugated ELDPs, 10 g/ml. Curve 2, FITC-conjugated ELDPs, 10 g/ml, with anti-CD11b antibody, 10 g/ml. Curves 3 and 4, FITC-conjugated ELDPs, 10 g/ml, with anti-SIRP antibody 5 and 10 g/ml, respectively. Curve 5, control with an unrelated FITC-conjugated second- ary antibody, 10 g/ml. Three cytometry tests were conducted.
Anti Sirp Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP-%CE%B1%2F%CE%B2+Antibody/10__1074_slash_jbc__m503866200-80-20-25
Average 85 stars, based on 1 article reviews
anti sirp antibody - by Bioz Stars, 2026-11
85/100 stars
  Buy from Supplier

94
Bio X Cell anti sirpα antibody
( A ) Flow cytometric detection of immune inhibitory receptors (left, PD-1; right, <t>SIRPα)</t> on the indicated immune cell types in kidneys of aged LOY and CT mice at 15 months after BMT (CT: n = 3; LOY: n = 3). Statistical significance was determined by a two-way ANOVA with Tukey’s post hoc test. ( B ) Flow cytometric analyses for PD-1 and SIRPα immune inhibitory receptor expression on the indicated immune cell types in injured kidneys of LOY and CT mice at 4 weeks after the administration of AA (CT: n = 6; LOY: n = 5). Statistical significance was determined by unpaired Student’s t tests. ( C ) Schematic of experiment assessing kidney injury in the hematopoietic LOY model. A series of peritoneal injections every 3 days with combined PD-1 and SIRPα ICI antibodies in LOY and CT mice was started 1 week after the administration of AA, and renal phenotypes were evaluated 4 weeks after the administration of AA. ( D ) Serum BUN amounts (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( E ) qRT-PCR analysis of kidney injury marker genes in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by unpaired Student’s t tests. ( F ) qRT-PCR analysis <t>of</t> <t>senescence-associated</t> genes in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( G ) Representative images and quantitative analysis of senescent area in kidneys, as stained with SA-β-gal (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Scale bars, 50 μm. Statistical significance was determined by unpaired Student’s t tests. ( H ) qRT-PCR analysis of the fibrosis-related gene Acta2 in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( I ) Representative images and quantitative analysis of fibrotic area in kidneys, as stained with picrosirius red (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Scale bars, 50 μm. Statistical significance was determined by unpaired Student’s t tests. Dots in all panels represent individual samples. Data are shown as the mean ± SEM (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, and NS ≥ 0.05).
Anti Sirpα Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/InVivoMAb+anti-mouse+CD172a/pmc12683723-437-31-33
Average 94 stars, based on 1 article reviews
anti sirpα antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology sirpα sirna
The <t>CD47‐SIRPα</t> axis impairs macrophage‐mediated phagocytosis and blockage of CD47‐SIRPα axis could improve the clearance of photoaged fibroblasts by macrophages. (A) Western blotting for SIRPα expression in macrophages co‐cultured with photoaged fibroblasts. (B) Representative pictures of SIRPα immunofluorescence staining. Red fluorescence for SIRPα, blue fluorescence for DAPI. Scale bar, 25 μm. (C) Macrophages were first co‐cultured with control or photoaged fibroblasts for 16 h and then switched to co‐culture with CFSE‐labeled (green) apoptotic Jurkat cells for 2 h. Representative images and quantified percentages of CFSE‐labeled (green fluorescence) apoptotic Jurkat cells phagocytosed by macrophages in each group. Scale bar, 50 μm. (D) Western blot analysis and quantification analysis of CD47 protein expression in photoaged fibroblasts transfected with CD47 <t>siRNA</t> or control siRNA. (E) Western blot analysis and quantification analysis of SIRPα protein expression in macrophages transfected with SIRPα siRNA or control siRNA. (F) Representative images of the photoaged fibroblasts‐macrophages co‐culture system with indicated treatments and related quantitative analysis of photoaged fibroblasts counts. The green color represents the residual CFSE‐labeled photoaged fibroblasts un‐eliminated by macrophages. Scale bar, 50 μm. Data are the means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001. FBs, fibroblasts. Mφ, macrophage.
Sirpα Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP-%CE%B1+siRNA/pmc11980025-81-19-23
Average 93 stars, based on 1 article reviews
sirpα sirna - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
Novus Biologicals triton x 100
The <t>CD47‐SIRPα</t> axis impairs macrophage‐mediated phagocytosis and blockage of CD47‐SIRPα axis could improve the clearance of photoaged fibroblasts by macrophages. (A) Western blotting for SIRPα expression in macrophages co‐cultured with photoaged fibroblasts. (B) Representative pictures of SIRPα immunofluorescence staining. Red fluorescence for SIRPα, blue fluorescence for DAPI. Scale bar, 25 μm. (C) Macrophages were first co‐cultured with control or photoaged fibroblasts for 16 h and then switched to co‐culture with CFSE‐labeled (green) apoptotic Jurkat cells for 2 h. Representative images and quantified percentages of CFSE‐labeled (green fluorescence) apoptotic Jurkat cells phagocytosed by macrophages in each group. Scale bar, 50 μm. (D) Western blot analysis and quantification analysis of CD47 protein expression in photoaged fibroblasts transfected with CD47 <t>siRNA</t> or control siRNA. (E) Western blot analysis and quantification analysis of SIRPα protein expression in macrophages transfected with SIRPα siRNA or control siRNA. (F) Representative images of the photoaged fibroblasts‐macrophages co‐culture system with indicated treatments and related quantitative analysis of photoaged fibroblasts counts. The green color represents the residual CFSE‐labeled photoaged fibroblasts un‐eliminated by macrophages. Scale bar, 50 μm. Data are the means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001. FBs, fibroblasts. Mφ, macrophage.
Triton X 100, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP+alpha%2FCD172a+Antibody+(OX-41)+-+BSA+Free/pmc10912295-60-41-52
Average 92 stars, based on 1 article reviews
triton x 100 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
OriGene human sirpα v2 cdna
( A ) Existing model by which <t>SIRPα</t> suppresses phagocytosis by interacting in trans with CD47 on target cells. See text for details. The 3 Ig-like domains of SIRPα (1 IgV and 2 IgCs) and the single Ig-V domain of CD47 are shown as ellipses. Mβs, macrophages. ( B ) Depiction of SIRPα variants and their functional characteristics. SIRPα FFFF contained substitution of tyrosine (Y)-to-phenylalanine (F) substitution at Y436, 460, 477, and 501; SIRPα ΔIC lacked most of the cytoplasmic domain of SIRPα, ending with arginine 401; SIRPα T96V carried a threonine (T)-to-valine (V) mutation at position 96 (shown by lavender star), which abolishes CD47-binding; SIRPα T96V,FFFF had the T96V and FFFF mutations; SIRPα T96V,ΔIC had the T96V and the ΔIC mutations. KO, knock-out. ITIM, immunoreceptor tyrosine-based inhibitory motif. ( C to G ) SIRPα variants or empty vector were expressed in SIRPα KO BMDMs and tested. Wild-type (WT) BMDMs were used as control. ( C ) Schematic representation of assays performed. Fc, fragment crystallizable. ( D ) Flow cytometry analyses of SIRPα expression and CD47-binding. APC, allophycocyanin. AF647, Alexa fluor 647. ( E and F ) Representative ( E ) and compiled data ( F ) of pHrodo-based phagocytosis assays using L1210 derivatives expressing Tac and opsonized with Tac monoclonal antibody (mAb) 7G7, as targets. Positive cells with percentages are boxed. G , Efficiency of phagocytosis inhibition in SIRPα KO BMDMs expressing or not the indicated SIRPα variants was calculated using the values in ( F ). SIRPα KO expressing WT SIRPα or empty vector displayed 100% and 0% inhibition efficiency, respectively. All data are means ± s.e.m., **** p < 0.0001. Results in ( D and E ) are representative of 6 independent experiments, except for SIRPα T96V , SIRPα T96V, FFFF and SIRPα T96V, ΔIC that are representative of 3 experiments. Results in ( F and G ) are pooled from a total of 6 mice studied in 6 independent experiments, except for SIRPα T96V , SIRPα T96V, FFFF and SIRPα T96V, ΔIC that involved 3 mice in 3 experiments. Each symbol in ( F ) represents one mouse.
Human Sirpα V2 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP+alpha+(SIRPA)+(BC026692)+Human+Untagged+Clone/bio_rxiv__2025__09__10__675342-131-0-8
Average 93 stars, based on 1 article reviews
human sirpα v2 cdna - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Proteintech sirpa
The primer sequences of the candidate genes
Sirpa, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP+alpha+Antibody/pmc10067389-76-27-31
Average 93 stars, based on 1 article reviews
sirpa - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


FIGURE 6. Binding of elastic lamina degradation peptides (ELDPs) to SIRP . A, co- immunoprecipitation of ELDPs with SIRP and phosphorylation of SIRP . Two tests were conducted. IP, immunoprecipitation. IB, immunoblotting. B, influence of anti-SIRP antibody on the binding of FITC-conjugated ELDPs to SIRP . Curve 1, FITC-conjugated ELDPs, 10 g/ml. Curve 2, FITC-conjugated ELDPs, 10 g/ml, with anti-CD11b antibody, 10 g/ml. Curves 3 and 4, FITC-conjugated ELDPs, 10 g/ml, with anti-SIRP antibody 5 and 10 g/ml, respectively. Curve 5, control with an unrelated FITC-conjugated second- ary antibody, 10 g/ml. Three cytometry tests were conducted.

Journal: Journal of Biological Chemistry

Article Title: Negative Regulation of Monocyte Adhesion to Arterial Elastic Laminae by Signal Regulatory Protein α and Src Homology 2 Domain-containing Protein-Tyrosine Phosphatase-1

doi: 10.1074/jbc.m503866200

Figure Lengend Snippet: FIGURE 6. Binding of elastic lamina degradation peptides (ELDPs) to SIRP . A, co- immunoprecipitation of ELDPs with SIRP and phosphorylation of SIRP . Two tests were conducted. IP, immunoprecipitation. IB, immunoblotting. B, influence of anti-SIRP antibody on the binding of FITC-conjugated ELDPs to SIRP . Curve 1, FITC-conjugated ELDPs, 10 g/ml. Curve 2, FITC-conjugated ELDPs, 10 g/ml, with anti-CD11b antibody, 10 g/ml. Curves 3 and 4, FITC-conjugated ELDPs, 10 g/ml, with anti-SIRP antibody 5 and 10 g/ml, respectively. Curve 5, control with an unrelated FITC-conjugated second- ary antibody, 10 g/ml. Three cytometry tests were conducted.

Article Snippet: The lysates weremeasured for total protein concentration, precleaned with protein A-conjugated agarose beads (10% packed beads, Upstate), immunoprecipitated with an anti-SIRP antibody (4 g/ml, sc-17803; Santa Cruz Biotechnology) at 4 °C for 4 h, and incubated with protein A-agarose beads (10% packed beads) at 4 °C for 4 h. The agarose beads were collected and treated with protein sample buffer at 100 °C for 5 min. Immunoprecipitates were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with the anti-SIRP antibody (0.5 g/ml).

Techniques: Binding Assay, Immunoprecipitation, Phospho-proteomics, Western Blot, Control, Cytometry

( A ) Flow cytometric detection of immune inhibitory receptors (left, PD-1; right, SIRPα) on the indicated immune cell types in kidneys of aged LOY and CT mice at 15 months after BMT (CT: n = 3; LOY: n = 3). Statistical significance was determined by a two-way ANOVA with Tukey’s post hoc test. ( B ) Flow cytometric analyses for PD-1 and SIRPα immune inhibitory receptor expression on the indicated immune cell types in injured kidneys of LOY and CT mice at 4 weeks after the administration of AA (CT: n = 6; LOY: n = 5). Statistical significance was determined by unpaired Student’s t tests. ( C ) Schematic of experiment assessing kidney injury in the hematopoietic LOY model. A series of peritoneal injections every 3 days with combined PD-1 and SIRPα ICI antibodies in LOY and CT mice was started 1 week after the administration of AA, and renal phenotypes were evaluated 4 weeks after the administration of AA. ( D ) Serum BUN amounts (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( E ) qRT-PCR analysis of kidney injury marker genes in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by unpaired Student’s t tests. ( F ) qRT-PCR analysis of senescence-associated genes in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( G ) Representative images and quantitative analysis of senescent area in kidneys, as stained with SA-β-gal (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Scale bars, 50 μm. Statistical significance was determined by unpaired Student’s t tests. ( H ) qRT-PCR analysis of the fibrosis-related gene Acta2 in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( I ) Representative images and quantitative analysis of fibrotic area in kidneys, as stained with picrosirius red (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Scale bars, 50 μm. Statistical significance was determined by unpaired Student’s t tests. Dots in all panels represent individual samples. Data are shown as the mean ± SEM (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, and NS ≥ 0.05).

Journal: Science translational medicine

Article Title: Hematopoietic loss of Y chromosome activates immune checkpoints and contributes to impaired senescent cell clearance and renal disease

doi: 10.1126/scitranslmed.adv4071

Figure Lengend Snippet: ( A ) Flow cytometric detection of immune inhibitory receptors (left, PD-1; right, SIRPα) on the indicated immune cell types in kidneys of aged LOY and CT mice at 15 months after BMT (CT: n = 3; LOY: n = 3). Statistical significance was determined by a two-way ANOVA with Tukey’s post hoc test. ( B ) Flow cytometric analyses for PD-1 and SIRPα immune inhibitory receptor expression on the indicated immune cell types in injured kidneys of LOY and CT mice at 4 weeks after the administration of AA (CT: n = 6; LOY: n = 5). Statistical significance was determined by unpaired Student’s t tests. ( C ) Schematic of experiment assessing kidney injury in the hematopoietic LOY model. A series of peritoneal injections every 3 days with combined PD-1 and SIRPα ICI antibodies in LOY and CT mice was started 1 week after the administration of AA, and renal phenotypes were evaluated 4 weeks after the administration of AA. ( D ) Serum BUN amounts (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( E ) qRT-PCR analysis of kidney injury marker genes in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by unpaired Student’s t tests. ( F ) qRT-PCR analysis of senescence-associated genes in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( G ) Representative images and quantitative analysis of senescent area in kidneys, as stained with SA-β-gal (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Scale bars, 50 μm. Statistical significance was determined by unpaired Student’s t tests. ( H ) qRT-PCR analysis of the fibrosis-related gene Acta2 in kidneys (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Statistical significance was determined by a one-way ANOVA with Tukey’s post hoc test. ( I ) Representative images and quantitative analysis of fibrotic area in kidneys, as stained with picrosirius red (CT control: n = 6; LOY control: n = 5; CT ICIs: n = 6; LOY ICIs: n = 6). Scale bars, 50 μm. Statistical significance was determined by unpaired Student’s t tests. Dots in all panels represent individual samples. Data are shown as the mean ± SEM (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, and NS ≥ 0.05).

Article Snippet: To evaluate the effect of treatment with ICIs on LOY-mediated renal damage in the murine model of AA-induced fibrosis and senescence, an anti–PD-1 antibody (Bio X Cell, no. BE0146) and an anti-SIRPα antibody (Bio X Cell, no. BE0322) were administered to hematopoietic mosaic LOY and CT mice 1 week after the administration of AA.

Techniques: Expressing, Control, Quantitative RT-PCR, Marker, Staining

The CD47‐SIRPα axis impairs macrophage‐mediated phagocytosis and blockage of CD47‐SIRPα axis could improve the clearance of photoaged fibroblasts by macrophages. (A) Western blotting for SIRPα expression in macrophages co‐cultured with photoaged fibroblasts. (B) Representative pictures of SIRPα immunofluorescence staining. Red fluorescence for SIRPα, blue fluorescence for DAPI. Scale bar, 25 μm. (C) Macrophages were first co‐cultured with control or photoaged fibroblasts for 16 h and then switched to co‐culture with CFSE‐labeled (green) apoptotic Jurkat cells for 2 h. Representative images and quantified percentages of CFSE‐labeled (green fluorescence) apoptotic Jurkat cells phagocytosed by macrophages in each group. Scale bar, 50 μm. (D) Western blot analysis and quantification analysis of CD47 protein expression in photoaged fibroblasts transfected with CD47 siRNA or control siRNA. (E) Western blot analysis and quantification analysis of SIRPα protein expression in macrophages transfected with SIRPα siRNA or control siRNA. (F) Representative images of the photoaged fibroblasts‐macrophages co‐culture system with indicated treatments and related quantitative analysis of photoaged fibroblasts counts. The green color represents the residual CFSE‐labeled photoaged fibroblasts un‐eliminated by macrophages. Scale bar, 50 μm. Data are the means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001. FBs, fibroblasts. Mφ, macrophage.

Journal: Journal of Cosmetic Dermatology

Article Title: Elevated CD47 Expression Impairs Elimination of Photoaged Fibroblasts by Macrophages and Serves as a Potential Biomarker for Photoaging

doi: 10.1111/jocd.70098

Figure Lengend Snippet: The CD47‐SIRPα axis impairs macrophage‐mediated phagocytosis and blockage of CD47‐SIRPα axis could improve the clearance of photoaged fibroblasts by macrophages. (A) Western blotting for SIRPα expression in macrophages co‐cultured with photoaged fibroblasts. (B) Representative pictures of SIRPα immunofluorescence staining. Red fluorescence for SIRPα, blue fluorescence for DAPI. Scale bar, 25 μm. (C) Macrophages were first co‐cultured with control or photoaged fibroblasts for 16 h and then switched to co‐culture with CFSE‐labeled (green) apoptotic Jurkat cells for 2 h. Representative images and quantified percentages of CFSE‐labeled (green fluorescence) apoptotic Jurkat cells phagocytosed by macrophages in each group. Scale bar, 50 μm. (D) Western blot analysis and quantification analysis of CD47 protein expression in photoaged fibroblasts transfected with CD47 siRNA or control siRNA. (E) Western blot analysis and quantification analysis of SIRPα protein expression in macrophages transfected with SIRPα siRNA or control siRNA. (F) Representative images of the photoaged fibroblasts‐macrophages co‐culture system with indicated treatments and related quantitative analysis of photoaged fibroblasts counts. The green color represents the residual CFSE‐labeled photoaged fibroblasts un‐eliminated by macrophages. Scale bar, 50 μm. Data are the means ± SD from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001. FBs, fibroblasts. Mφ, macrophage.

Article Snippet: To determine the role of CD47‐SIRPα axis in this process, CD47 siRNA (sc‐35 006, Santa Cruz, CA, USA) and SIRPα siRNA (sc‐44 106, Santa Cruz) were applied to block their expression using Lipo3000 (Invitrogen, CA, USA), respectively.

Techniques: Western Blot, Expressing, Cell Culture, Immunofluorescence, Staining, Fluorescence, Control, Co-Culture Assay, Labeling, Transfection

Increased number of CD47 + senescent fibroblasts and SIRPα + macrophages in the sun‐exposed aged skin. (A) Triple immunofluorescence staining for CD47 (deep red), Vimentin (green) and p21 (red) in skin tissues of sun‐protected and sun‐exposed groups. Blue: DAPI nuclear counterstaining. Bar graphs represent the number of CD47, p16, and Vimentin triple‐positive cells. Scale bar, 50 μm. (B) Double immunofluorescence staining for CD68 (green) and SIRPα (red) in skin tissues of each group. Blue: DAPI nuclear counterstaining. Bar graphs represent the number of CD68/SIRPα double‐positive cells. Data are the means ± SD from three independent experiments. *** p < 0.001. FBs, fibroblasts. Mφ, macrophage.

Journal: Journal of Cosmetic Dermatology

Article Title: Elevated CD47 Expression Impairs Elimination of Photoaged Fibroblasts by Macrophages and Serves as a Potential Biomarker for Photoaging

doi: 10.1111/jocd.70098

Figure Lengend Snippet: Increased number of CD47 + senescent fibroblasts and SIRPα + macrophages in the sun‐exposed aged skin. (A) Triple immunofluorescence staining for CD47 (deep red), Vimentin (green) and p21 (red) in skin tissues of sun‐protected and sun‐exposed groups. Blue: DAPI nuclear counterstaining. Bar graphs represent the number of CD47, p16, and Vimentin triple‐positive cells. Scale bar, 50 μm. (B) Double immunofluorescence staining for CD68 (green) and SIRPα (red) in skin tissues of each group. Blue: DAPI nuclear counterstaining. Bar graphs represent the number of CD68/SIRPα double‐positive cells. Data are the means ± SD from three independent experiments. *** p < 0.001. FBs, fibroblasts. Mφ, macrophage.

Article Snippet: To determine the role of CD47‐SIRPα axis in this process, CD47 siRNA (sc‐35 006, Santa Cruz, CA, USA) and SIRPα siRNA (sc‐44 106, Santa Cruz) were applied to block their expression using Lipo3000 (Invitrogen, CA, USA), respectively.

Techniques: Immunofluorescence, Staining, Double Immunofluorescence Staining

( A ) Existing model by which SIRPα suppresses phagocytosis by interacting in trans with CD47 on target cells. See text for details. The 3 Ig-like domains of SIRPα (1 IgV and 2 IgCs) and the single Ig-V domain of CD47 are shown as ellipses. Mβs, macrophages. ( B ) Depiction of SIRPα variants and their functional characteristics. SIRPα FFFF contained substitution of tyrosine (Y)-to-phenylalanine (F) substitution at Y436, 460, 477, and 501; SIRPα ΔIC lacked most of the cytoplasmic domain of SIRPα, ending with arginine 401; SIRPα T96V carried a threonine (T)-to-valine (V) mutation at position 96 (shown by lavender star), which abolishes CD47-binding; SIRPα T96V,FFFF had the T96V and FFFF mutations; SIRPα T96V,ΔIC had the T96V and the ΔIC mutations. KO, knock-out. ITIM, immunoreceptor tyrosine-based inhibitory motif. ( C to G ) SIRPα variants or empty vector were expressed in SIRPα KO BMDMs and tested. Wild-type (WT) BMDMs were used as control. ( C ) Schematic representation of assays performed. Fc, fragment crystallizable. ( D ) Flow cytometry analyses of SIRPα expression and CD47-binding. APC, allophycocyanin. AF647, Alexa fluor 647. ( E and F ) Representative ( E ) and compiled data ( F ) of pHrodo-based phagocytosis assays using L1210 derivatives expressing Tac and opsonized with Tac monoclonal antibody (mAb) 7G7, as targets. Positive cells with percentages are boxed. G , Efficiency of phagocytosis inhibition in SIRPα KO BMDMs expressing or not the indicated SIRPα variants was calculated using the values in ( F ). SIRPα KO expressing WT SIRPα or empty vector displayed 100% and 0% inhibition efficiency, respectively. All data are means ± s.e.m., **** p < 0.0001. Results in ( D and E ) are representative of 6 independent experiments, except for SIRPα T96V , SIRPα T96V, FFFF and SIRPα T96V, ΔIC that are representative of 3 experiments. Results in ( F and G ) are pooled from a total of 6 mice studied in 6 independent experiments, except for SIRPα T96V , SIRPα T96V, FFFF and SIRPα T96V, ΔIC that involved 3 mice in 3 experiments. Each symbol in ( F ) represents one mouse.

Journal: bioRxiv

Article Title: Binding of inhibitory checkpoints to CD18 in cis hinders anti-cancer immune responses

doi: 10.1101/2025.09.10.675342

Figure Lengend Snippet: ( A ) Existing model by which SIRPα suppresses phagocytosis by interacting in trans with CD47 on target cells. See text for details. The 3 Ig-like domains of SIRPα (1 IgV and 2 IgCs) and the single Ig-V domain of CD47 are shown as ellipses. Mβs, macrophages. ( B ) Depiction of SIRPα variants and their functional characteristics. SIRPα FFFF contained substitution of tyrosine (Y)-to-phenylalanine (F) substitution at Y436, 460, 477, and 501; SIRPα ΔIC lacked most of the cytoplasmic domain of SIRPα, ending with arginine 401; SIRPα T96V carried a threonine (T)-to-valine (V) mutation at position 96 (shown by lavender star), which abolishes CD47-binding; SIRPα T96V,FFFF had the T96V and FFFF mutations; SIRPα T96V,ΔIC had the T96V and the ΔIC mutations. KO, knock-out. ITIM, immunoreceptor tyrosine-based inhibitory motif. ( C to G ) SIRPα variants or empty vector were expressed in SIRPα KO BMDMs and tested. Wild-type (WT) BMDMs were used as control. ( C ) Schematic representation of assays performed. Fc, fragment crystallizable. ( D ) Flow cytometry analyses of SIRPα expression and CD47-binding. APC, allophycocyanin. AF647, Alexa fluor 647. ( E and F ) Representative ( E ) and compiled data ( F ) of pHrodo-based phagocytosis assays using L1210 derivatives expressing Tac and opsonized with Tac monoclonal antibody (mAb) 7G7, as targets. Positive cells with percentages are boxed. G , Efficiency of phagocytosis inhibition in SIRPα KO BMDMs expressing or not the indicated SIRPα variants was calculated using the values in ( F ). SIRPα KO expressing WT SIRPα or empty vector displayed 100% and 0% inhibition efficiency, respectively. All data are means ± s.e.m., **** p < 0.0001. Results in ( D and E ) are representative of 6 independent experiments, except for SIRPα T96V , SIRPα T96V, FFFF and SIRPα T96V, ΔIC that are representative of 3 experiments. Results in ( F and G ) are pooled from a total of 6 mice studied in 6 independent experiments, except for SIRPα T96V , SIRPα T96V, FFFF and SIRPα T96V, ΔIC that involved 3 mice in 3 experiments. Each symbol in ( F ) represents one mouse.

Article Snippet: Human SIRPα V2 cDNA (Cat: SC125649) was from OriGene (Rockville, MD).

Techniques: Functional Assay, Mutagenesis, Binding Assay, Knock-Out, Plasmid Preparation, Control, Flow Cytometry, Expressing, Inhibition

( A and B ) Immunoprecipitation followed by mass spectrometry of SIRPα-associated proteins. ( A ) Schematic representation of assay. ( B ) Plasma membrane-associated proteins found in SIRPα immunoprecipitates from WT BMDMs, but not from SIRPα KO BMDMs. c , Co-immunoprecipitation assay of SIRPα, CD18 and CD11b in WT and SIRPα KO BMDMs. IP, immunoprecipitation. Abs, antibodies. ( D to F ) FRET assays. ( D ) Schematic representation of FRET assay in HEK293T cells. ( E and F ) Representative confocal microscopy images ( E ) and compiled data ( F ) of FRET assays with donor-labeled SIRPα, acceptor-labeled CD18 and unlabeled CD11b in the presence of control (Ctrl) IgG, CD18 mAb GAME-46 or CD11b mAb 5C6. Yellow to purple spectrum denotes strong to weak FRET. DIC, differential interference contrast. Scale bars, 5 μm. ( G and H ) LUV-FRET assay. ( G ) Schematic representation of LUV-FRET assay. ( H ), Time-course of donor-labeled SIRPα fluorescence intensity after addition of acceptor-labeled CD18 or CD11b, monitored with a real-time plate reader. All data are means ± s.e.m. ns, not significant, **** p < 0.0001. Results in ( C , E and H ) are representative of 3 independent experiments. Results in ( B and F ) are pooled from a total of 3 independent experiments. Each symbol in ( F ) represents one cell.

Journal: bioRxiv

Article Title: Binding of inhibitory checkpoints to CD18 in cis hinders anti-cancer immune responses

doi: 10.1101/2025.09.10.675342

Figure Lengend Snippet: ( A and B ) Immunoprecipitation followed by mass spectrometry of SIRPα-associated proteins. ( A ) Schematic representation of assay. ( B ) Plasma membrane-associated proteins found in SIRPα immunoprecipitates from WT BMDMs, but not from SIRPα KO BMDMs. c , Co-immunoprecipitation assay of SIRPα, CD18 and CD11b in WT and SIRPα KO BMDMs. IP, immunoprecipitation. Abs, antibodies. ( D to F ) FRET assays. ( D ) Schematic representation of FRET assay in HEK293T cells. ( E and F ) Representative confocal microscopy images ( E ) and compiled data ( F ) of FRET assays with donor-labeled SIRPα, acceptor-labeled CD18 and unlabeled CD11b in the presence of control (Ctrl) IgG, CD18 mAb GAME-46 or CD11b mAb 5C6. Yellow to purple spectrum denotes strong to weak FRET. DIC, differential interference contrast. Scale bars, 5 μm. ( G and H ) LUV-FRET assay. ( G ) Schematic representation of LUV-FRET assay. ( H ), Time-course of donor-labeled SIRPα fluorescence intensity after addition of acceptor-labeled CD18 or CD11b, monitored with a real-time plate reader. All data are means ± s.e.m. ns, not significant, **** p < 0.0001. Results in ( C , E and H ) are representative of 3 independent experiments. Results in ( B and F ) are pooled from a total of 3 independent experiments. Each symbol in ( F ) represents one cell.

Article Snippet: Human SIRPα V2 cDNA (Cat: SC125649) was from OriGene (Rockville, MD).

Techniques: Immunoprecipitation, Mass Spectrometry, Clinical Proteomics, Membrane, Co-Immunoprecipitation Assay, Confocal Microscopy, Labeling, Control, Fluorescence

( A and B ) FRET assays with SIRPα and SIRPβ1a. ( A ) A schematic representation of SIRPα and SIRPβ1a, with their 1 IgV domain and 2 IgC domains, is depicted. ( B ) Compiled data of 3 independent experiments using donor-labeled SIRPα or SIRPβ1a, acceptor-labeled CD18 and unlabeled CD11b, as done for , D to F. ( C and D ) FRET assays using SIRPα IgV domain. ( C ) A schematic representation of a SIRPα variant having only the IgV domain is shown. ( D ) Compiled data of 3 independent experiments using donor-labeled SIRPα IgV, acceptor-labeled CD18 and unlabeled CD11b, as done for , D to F. ( E - H ) FRET assays using SIRPα variants carrying non-conserved residues from SIRPβ1a. ( E and G ) Schematic representations of SIRPα variants. ( F and H ) Compiled data from 3 independent experiments using donor-labeled SIRPα variants, acceptor-labeled CD18 and unlabeled CD11b, as done for , D to F. ( I to K ) Proximity ligation assay (PLA) of SIRPα and CD18 in BMDMs expressing or not the indicated SIRPα variants. (I) Flow cytometry analyses of SIRPα expression. ( J and K ) Representative confocal microscopy images ( J ) and compiled data from 3 independent experiments ( K ) of PLA for SIRPα and CD18. Scale bar, 10 μm. All data are means ± s.e.m. ns, not significant, **** p < 0.0001. Results in ( I and J ) are representative of 3 independent experiments. Results in ( B , D , F , H and K ) are pooled from 3 independent experiments. Each symbol in ( B , D , F , H and K ) represents one cell or mouse.

Journal: bioRxiv

Article Title: Binding of inhibitory checkpoints to CD18 in cis hinders anti-cancer immune responses

doi: 10.1101/2025.09.10.675342

Figure Lengend Snippet: ( A and B ) FRET assays with SIRPα and SIRPβ1a. ( A ) A schematic representation of SIRPα and SIRPβ1a, with their 1 IgV domain and 2 IgC domains, is depicted. ( B ) Compiled data of 3 independent experiments using donor-labeled SIRPα or SIRPβ1a, acceptor-labeled CD18 and unlabeled CD11b, as done for , D to F. ( C and D ) FRET assays using SIRPα IgV domain. ( C ) A schematic representation of a SIRPα variant having only the IgV domain is shown. ( D ) Compiled data of 3 independent experiments using donor-labeled SIRPα IgV, acceptor-labeled CD18 and unlabeled CD11b, as done for , D to F. ( E - H ) FRET assays using SIRPα variants carrying non-conserved residues from SIRPβ1a. ( E and G ) Schematic representations of SIRPα variants. ( F and H ) Compiled data from 3 independent experiments using donor-labeled SIRPα variants, acceptor-labeled CD18 and unlabeled CD11b, as done for , D to F. ( I to K ) Proximity ligation assay (PLA) of SIRPα and CD18 in BMDMs expressing or not the indicated SIRPα variants. (I) Flow cytometry analyses of SIRPα expression. ( J and K ) Representative confocal microscopy images ( J ) and compiled data from 3 independent experiments ( K ) of PLA for SIRPα and CD18. Scale bar, 10 μm. All data are means ± s.e.m. ns, not significant, **** p < 0.0001. Results in ( I and J ) are representative of 3 independent experiments. Results in ( B , D , F , H and K ) are pooled from 3 independent experiments. Each symbol in ( B , D , F , H and K ) represents one cell or mouse.

Article Snippet: Human SIRPα V2 cDNA (Cat: SC125649) was from OriGene (Rockville, MD).

Techniques: Labeling, Variant Assay, Proximity Ligation Assay, Expressing, Flow Cytometry, Confocal Microscopy

( A to C ) The impact of SIRPα variants defective in CD18-binding, CD47-binding or phosphatase signaling, alone or in combination, expressed in BMDMs, was analyzed. ( A ) Schematic depictions of SIRPα variants, as was done for . SIRPα R91T carried an arginine (R)-to-threonine (T) mutation at position 91 (shown by blue star), which abolished CD18-binding. ( B ) Phagocytosis assays of IgG-opsonized L1210 cells by BMDMs, as was done for . ( C ) Efficiency of phagocytosis inhibition was calculated as for , using values from . ( D and E ) Representative flow cytometry profiles ( D ) and compiled data from 3 independent experiments ( E ) of ICAM-1-binding using SIRPα KO BMDMs expressing WT SIRPα or SIRPα R91T BMDMs, in the presence or absence of FcR triggering using mouse IgG2a. ( F and G ) The impact of a SIRPα variant carrying the isoleucine-to-glycine 332 (I332G) mutation, expressed in SIRPα KO BMDMs, was analyzed. (F) Flow cytometry analyses of CD11b expression. ( G ) Compiled data from 3 independent phagocytosis assays, assessed by microscopy. ( H ) FRET assays of donor-labeled SIRPα, acceptor-labeled CD18 and unlabeled CD11b in the presence of WT CD11b or CD11b I332G , as was done for , D to F. ( I ) FRET assays of donor-labeled human SIRPα version (V) 1 or V2 with acceptor-labeled human CD18 and unlabeled human CD11b, in the presence of Ctrl IgG, human CD18 mAbs CBR LFA1/2 or TS1/18, as was done for , D to F. ( J ) Phagocytosis of human lymphoma cells Raji, which were opsonized with CD20 mAbs, by human peripheral blood monocyte (PBMC)-derived macrophages, in the presence of the indicated mAbs, was assessed by microscopy. All data are means ± s.e.m. ns, not significant; * p < 0.05, ** p < 0.01 and **** p < 0.0001. Results in ( D and F ) are representative of 3 independent experiments. Results in ( B , C , E and G to J ) are pooled from 3 independent experiments. Each symbol in ( B , E and G to J ) represents one cell, mouse or healthy donor.

Journal: bioRxiv

Article Title: Binding of inhibitory checkpoints to CD18 in cis hinders anti-cancer immune responses

doi: 10.1101/2025.09.10.675342

Figure Lengend Snippet: ( A to C ) The impact of SIRPα variants defective in CD18-binding, CD47-binding or phosphatase signaling, alone or in combination, expressed in BMDMs, was analyzed. ( A ) Schematic depictions of SIRPα variants, as was done for . SIRPα R91T carried an arginine (R)-to-threonine (T) mutation at position 91 (shown by blue star), which abolished CD18-binding. ( B ) Phagocytosis assays of IgG-opsonized L1210 cells by BMDMs, as was done for . ( C ) Efficiency of phagocytosis inhibition was calculated as for , using values from . ( D and E ) Representative flow cytometry profiles ( D ) and compiled data from 3 independent experiments ( E ) of ICAM-1-binding using SIRPα KO BMDMs expressing WT SIRPα or SIRPα R91T BMDMs, in the presence or absence of FcR triggering using mouse IgG2a. ( F and G ) The impact of a SIRPα variant carrying the isoleucine-to-glycine 332 (I332G) mutation, expressed in SIRPα KO BMDMs, was analyzed. (F) Flow cytometry analyses of CD11b expression. ( G ) Compiled data from 3 independent phagocytosis assays, assessed by microscopy. ( H ) FRET assays of donor-labeled SIRPα, acceptor-labeled CD18 and unlabeled CD11b in the presence of WT CD11b or CD11b I332G , as was done for , D to F. ( I ) FRET assays of donor-labeled human SIRPα version (V) 1 or V2 with acceptor-labeled human CD18 and unlabeled human CD11b, in the presence of Ctrl IgG, human CD18 mAbs CBR LFA1/2 or TS1/18, as was done for , D to F. ( J ) Phagocytosis of human lymphoma cells Raji, which were opsonized with CD20 mAbs, by human peripheral blood monocyte (PBMC)-derived macrophages, in the presence of the indicated mAbs, was assessed by microscopy. All data are means ± s.e.m. ns, not significant; * p < 0.05, ** p < 0.01 and **** p < 0.0001. Results in ( D and F ) are representative of 3 independent experiments. Results in ( B , C , E and G to J ) are pooled from 3 independent experiments. Each symbol in ( B , E and G to J ) represents one cell, mouse or healthy donor.

Article Snippet: Human SIRPα V2 cDNA (Cat: SC125649) was from OriGene (Rockville, MD).

Techniques: Binding Assay, Mutagenesis, Inhibition, Flow Cytometry, Expressing, Variant Assay, Microscopy, Labeling, Derivative Assay

( A ) FRET assays of donor-labeled mouse SIRPα with acceptor-labeled mouse CD18 and unlabeled mouse CD11b, in the presence of Fc-silent mouse SIRPα mAbs, as was done for , D to F. ( B ) Binding of a soluble CD47-Fc fusion protein to EL-4 cells, expressing or not expressing mouse SIRPα, was studied by flow cytometry. ( C to K ) Generation and impact of bispecific antibody (BsAb) against mouse SIRPα. ( C ) Schematic representation of Fc-silent BsAb combining one arm of mAb #17 with one arm of mAb #27, using the “knob-into-hole” technology. Phagocytosis of IgG-opsonized L1210 cells ( D ) and EL-4 cells ( E ) by WT BMDMs, in the presence of mAbs, was assessed by a microscopy assays. ( F to K ) Schematic depictions of the assays are shown in (F and I). RAG-1 KO mice injected subcutaneously with Tac + L1210 cells ( G and H ), or C57BL/6J mice injected subcutaneously with Tac + EL-4 cells ( J and K ), were treated by intraperitoneal injection of Fc-silent mAbs, alongside Tac mAb 7G7 for opsonization. Tumor volume was measured using a caliper ( G and J ) and survival was recorded ( H and K ). ( L ) FRET assays of donor-labeled human SIRPα V1 or V2 with acceptor-labeled human CD18 and unlabeled human CD11b in the presence of Fc-silent Ctrl IgG and human SIRPα mAbs KWAR23, 40A, 50A, or 18D5, as was done for , D to F. The mAbs were rendered Fc-silent by the LALAPG mutation. ( M ) Phagocytosis of IgG-opsonized Raji cells by human macrophages in the presence of Fc-silent Ctrl IgG and SIRPα mAbs KWAR23, 40A, 50A, or 18D5, was assayed as for . ( N ) FRET assays of donor-labeled human 2B4 (SLAMF4), PD-1 or LILRB1 with acceptor-labeled human CD18, in the presence of Ctrl IgG or human CD18 mAb were done as for , D to F. All data are means ± s.e.m. ns, not significant; * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. Results are pooled from a total of two ( H and K ), three ( A , D , E , G , J , L and N ) or five ( B and M ) independent experiments. Each symbol in ( A , D , E and L to N ) represents one healthy donor, cell or mouse.

Journal: bioRxiv

Article Title: Binding of inhibitory checkpoints to CD18 in cis hinders anti-cancer immune responses

doi: 10.1101/2025.09.10.675342

Figure Lengend Snippet: ( A ) FRET assays of donor-labeled mouse SIRPα with acceptor-labeled mouse CD18 and unlabeled mouse CD11b, in the presence of Fc-silent mouse SIRPα mAbs, as was done for , D to F. ( B ) Binding of a soluble CD47-Fc fusion protein to EL-4 cells, expressing or not expressing mouse SIRPα, was studied by flow cytometry. ( C to K ) Generation and impact of bispecific antibody (BsAb) against mouse SIRPα. ( C ) Schematic representation of Fc-silent BsAb combining one arm of mAb #17 with one arm of mAb #27, using the “knob-into-hole” technology. Phagocytosis of IgG-opsonized L1210 cells ( D ) and EL-4 cells ( E ) by WT BMDMs, in the presence of mAbs, was assessed by a microscopy assays. ( F to K ) Schematic depictions of the assays are shown in (F and I). RAG-1 KO mice injected subcutaneously with Tac + L1210 cells ( G and H ), or C57BL/6J mice injected subcutaneously with Tac + EL-4 cells ( J and K ), were treated by intraperitoneal injection of Fc-silent mAbs, alongside Tac mAb 7G7 for opsonization. Tumor volume was measured using a caliper ( G and J ) and survival was recorded ( H and K ). ( L ) FRET assays of donor-labeled human SIRPα V1 or V2 with acceptor-labeled human CD18 and unlabeled human CD11b in the presence of Fc-silent Ctrl IgG and human SIRPα mAbs KWAR23, 40A, 50A, or 18D5, as was done for , D to F. The mAbs were rendered Fc-silent by the LALAPG mutation. ( M ) Phagocytosis of IgG-opsonized Raji cells by human macrophages in the presence of Fc-silent Ctrl IgG and SIRPα mAbs KWAR23, 40A, 50A, or 18D5, was assayed as for . ( N ) FRET assays of donor-labeled human 2B4 (SLAMF4), PD-1 or LILRB1 with acceptor-labeled human CD18, in the presence of Ctrl IgG or human CD18 mAb were done as for , D to F. All data are means ± s.e.m. ns, not significant; * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. Results are pooled from a total of two ( H and K ), three ( A , D , E , G , J , L and N ) or five ( B and M ) independent experiments. Each symbol in ( A , D , E and L to N ) represents one healthy donor, cell or mouse.

Article Snippet: Human SIRPα V2 cDNA (Cat: SC125649) was from OriGene (Rockville, MD).

Techniques: Labeling, Binding Assay, Expressing, Flow Cytometry, Microscopy, Injection, Mutagenesis

The primer sequences of the candidate genes

Journal: Cancer Science

Article Title: Characterization of myeloid signature genes for predicting prognosis and immune landscape in Ewing sarcoma

doi: 10.1111/cas.15688

Figure Lengend Snippet: The primer sequences of the candidate genes

Article Snippet: All tissue slices were subjected to a series of steps such as dewaxing, antigen retrieval, blocking, primary antibody incubation, and secondary antibody incubation, including CTSD (Proteintech, 21327‐1‐AP), SIRPA (Affinity, AF0253), FN1 (Proteintech, 15613‐1‐AP), CD8 (Proteintech, 66868‐1‐lg), CD206 (Proteintech, 60143‐1‐lg), CD66b (Abcam, ab300122), and CD57 (Servicebio, GB113461).

Techniques: Sequencing

In vitro validation of CTSD, SIRPA, and FN1 expression. A, Western blotting showing protein expression levels of CTSD, SIRPA, and FN1 in Ewing sarcoma (EWS) cell lines and normal controls; B‐D, Quantitative real‐time PCR showing the relative mRNA expression levels of CTSD, SIRPA, and FN1 in EWS cell lines and normal controls. E‐G, Representative immunohistochemistry staining of CTSD, SIRPA, and FN1 in EWS tissue and matched para‐cancer. H‐J, Quantitative analysis of the positive rate of pathological stained sections for these three genes. * p < 0.05; ** p < 0.01; *** p < 0.001

Journal: Cancer Science

Article Title: Characterization of myeloid signature genes for predicting prognosis and immune landscape in Ewing sarcoma

doi: 10.1111/cas.15688

Figure Lengend Snippet: In vitro validation of CTSD, SIRPA, and FN1 expression. A, Western blotting showing protein expression levels of CTSD, SIRPA, and FN1 in Ewing sarcoma (EWS) cell lines and normal controls; B‐D, Quantitative real‐time PCR showing the relative mRNA expression levels of CTSD, SIRPA, and FN1 in EWS cell lines and normal controls. E‐G, Representative immunohistochemistry staining of CTSD, SIRPA, and FN1 in EWS tissue and matched para‐cancer. H‐J, Quantitative analysis of the positive rate of pathological stained sections for these three genes. * p < 0.05; ** p < 0.01; *** p < 0.001

Article Snippet: All tissue slices were subjected to a series of steps such as dewaxing, antigen retrieval, blocking, primary antibody incubation, and secondary antibody incubation, including CTSD (Proteintech, 21327‐1‐AP), SIRPA (Affinity, AF0253), FN1 (Proteintech, 15613‐1‐AP), CD8 (Proteintech, 66868‐1‐lg), CD206 (Proteintech, 60143‐1‐lg), CD66b (Abcam, ab300122), and CD57 (Servicebio, GB113461).

Techniques: In Vitro, Biomarker Discovery, Expressing, Western Blot, Real-time Polymerase Chain Reaction, Immunohistochemistry, Staining